News >

CAR T-Cell Therapy Active in High-Risk, Refractory CLL

Published: Wednesday, Sep 20, 2017

Cameron J. Turtle, PhD
Cameron J. Turtle, PhD
Patients with refractory chronic lymphocytic leukemia (CLL) achieved a high-response rate with CD19-targeted CAR T-cell therapy, results of a small, single-arm study showed.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication